Clinical partnership Oncotelic operates a capital efficient partnership and joint venture driven model with programs advanced into late-stage development, presenting clear paths to value and multiple collaboration angles for biotech, pharma, and investment partners seeking co-development and risk sharing.

Deciparticle platform The Deciparticle nanomedicine technology and the SapuNano collaboration open opportunities to license or co-develop IV hydrophobic drugs, offering improved tissue penetration and pharmacology that could appeal to companies facing delivery and toxicity challenges.

TGFB2 focus TGFB2 based therapeutics targeting tumor immune evasion and fibrosis align with oncology players seeking solutions in immune modulation and resistance mechanisms, presenting a path for strategic alliances around late-stage assets and translational biomarkers.

AI driven PDAOAI platform enables evidence interrogation, biomarker discovery, and translational insights, providing potential value-add services for collaborators needing advanced analytics, trial design optimization, and imaging/biomarker strategy support.

Global expansion Recent and planned activities include European expansion and a Hong Kong IPO pathway through Sapu Therapeutics, signaling readiness for international partnerships, licensing, and manufacturing collaborations to scale clinical programs.